Conventional anticancer therapies lack specificity, resulting in toxicity to healthy tissue. Antibody-drug conjugates (ADCs) constitute a therapeutic modality in which a cytotoxic agent is chemically linked to an antibody that recognizes a tumor-associated antigen. The ADC platform includes a growing repertoire of cytotoxic payloads, linker technologies and conjugation methods; two ADCs are FDA-approved and over 30 are in clinical development. This symposium highlights advances in ADC research, clinical development and regulatory perspectives. Topics span early phase research focused on development of novel linker-payload and conjugation chemistries, clinical concepts and development of biomarkers and patient selection strategies.

Organizers
Mercedes Beyna, MS, Pfizer
Nahor Haddish-Berhane, PhD, Pfizer
Jennifer Henry, PhD, The New York Academy of Sciences
Mauricio Leal, PhD, Pfizer
Puja Sapra, PhD, Pfizer
Dhaval K. Shah, PhD, The State University of New York at Buffalo

Speakers
Ho Sung Cho, PhD, Ambrx, Inc.
Nahor Haddish-Berhane, PhD, Pfizer
Sara Hurvitz, MD, UCLA Medical Center
Omar Kabbarah, PhD, Genentech Inc.
Puja Sapra, PhD, Pfizer
Melissa M. Schutten, DVM, PhD, DACVP, Genentech Inc.
Peter D. Senter, PhD, Seattle Genetics, Inc.
Dhaval K. Shah, PhD, The State University of New York at Buffalo
Stacey S. Shord, PharmD, BCOP, FCCP, Food and Drug Administration

Presented by the Biochemical Pharmacology Discussion Group at the New York Academy of Sciences

The Biochemical Pharmacology Discussion Group is proudly supported by

Boehringer Ingelheim, Merck, Pfizer, WilmerHale

Mission Partner support for the Frontiers of Science program provided by Pfizer